3 documents found, page 1 of 1
Blood-borne virus testing in European emergency departments: current evidence a...
Smout, E; Ruf, M; Buti, M; Pinto, IV; Nebbia, G; Hunter, L; Aldersley, MA; Esteves, C; Medina, D; Llaneras, J; Douthwaite, S; Page, EEInnovative testing approaches are needed to meet global targets for the blood-borne viruses (BBVs) HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). We conducted a systematic review of BBV testing in emergency departments (EDs) in Europe to evaluate prevalence, effectiveness of ED testing and linkage to care (LTC). We searched PubMed, Embase and Cochrane Library for articles on ED BBV testing published ...
In Vitro Evaluation of Novel Reverse Transcriptase Inhibitors TAF (Tenofovir Al...
Bártolo, I; Borrego, P; Gomes, P; Gonçalves, F; Caixas, U; Pinto, IV; Taveira, NNew antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients experiencing virologic failure. TAF and OBP-601 were tested against twelve primary isolates obtained from nine drug-e...
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir al...
Bártolo, I; Borrego, P; Gomes, P; Gonçalves, F; Caixas, U; Pinto, IV; Taveira, NNew antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients experiencing virologic failure. TAF and OBP-601 were tested against twelve primary isolates obtained from nine drug-e...